Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019
(COVID-19) illness were available within a year of the pandemic being declared but there …

The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted
in significant casualties and put immense strain on public health systems worldwide, leading …

Severe cases of coronavirus disease 2019 (COVID-19) managed in the intensive care unit
are prone to complications, including secondary infections with opportunistic fungal …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was the seventh
known human coronavirus, and it was identified in Wuhan, Hubei province, China, in 2020. It …

Background Azithromycin (AZM), sold under the name Zithromax, is classified as a
macrolide. It has many benefits due to its immunomodulatory, anti‐inflammatory, and …

The COVID-19 pandemic has caused substantial losses worldwide in people's lives, health,
and property. Currently, COVID-19 is still prominent worldwide without any specific drug …

Background Limited data exists evaluating predictors of long-term outcomes after
hospitalization for COVID-19. Methods We conducted a prospective, longitudinal cohort …

Acute lung injury (ALI) is one of the adverse effects of the antineoplastic agent cisplatin
(CIS). Oxidative stress, inflammation, and necroptosis are linked to the emergence of lung …

Background Lower respiratory tract infections are frequently treated with antibiotics, despite
a viral cause in many cases. It remains unknown whether low procalcitonin concentrations …

Numbers of patients with coronavirus disease 2019 (COVID-19) have increased rapidly
worldwide. Plasma levels of full-length galectin-9 (FL-Gal9) and osteopontin (FL-OPN) as …